Non-contraceptive benefits of intrauterine levonorgestrel administration: why not?

Lorenzo Sabbioni, Sabbioni L, Felice Petraglia, Petraglia F, Stefano Luisi
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2017 · vol. 33(11) , pp. 822–829 · doi:10.1080/09513590.2017.1334198 · PMID:28586290 · W2622073495
Review OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This paper reviews the noncontraceptive benefits of levonorgestrel intrauterine systems for gynecological conditions like abnormal bleeding and fibroids, arguing for their broader use beyond contraception.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Levonorgestrel intrauterine systems (LNG-IUS) represent a modern therapy for an array of preexisting gynecological conditions, though they were first marketed in Finland in 1990. However, there are countries in which their use is extremely limited by social and cultural factors. This manuscript describes the possible reasons for this misuse, taking in consideration the clinical noncontraceptive benefits of intrauterine levonorgestrel in routinary practice. Medical diseases in which LNG-IUS represent a treatment include abnormal uterine bleeding, iron-deficiency anemia, endometrial hyperplasia, uterine fibroids, adenomyosis, endometriosis, and coagulopathies. The advantage of reducing the need for more radical treatments such as surgery or hysterectomy is well demonstrated, with remarkable benefits for patients. However, in many countries, surgery is still used as a first-line treatment and there is a need to define who could benefit from a less invasive option. It seems clear that such a reduced use of LNG-IUS depends on factors that imply both patients and practitioners, and that the role of counseling is becoming a key component in the decision-making process to reach the ultimate goal of compliance.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Contraceptive Agents, Female Genital Diseases, Female Intrauterine Devices, Medicated Levonorgestrel Contraceptive Agents, Female Contraceptive Agents, Female Female Female Genital Diseases, Female Genital Diseases, Female Humans Humans Intrauterine Devices, Medicated Intrauterine Devices, Medicated Levonorgestrel Levonorgestrel

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (46)

Cited by (9)

Source provenance

europepmc
last seen: 2026-10-10T06:11:15.153948+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:20:02.015990+00:00
License: CC0 · commercial use OK